Abstract #1574

Prevalence of Nephrogenic Systemic Fibrosis (NSF) in Dialysis Patients: Final Results of the Pro-FINEST Study

Sabine Amet¹, Vincent Launay-Vacher¹, Gilbert Deray², Aurore Tricotel³, Camille Francs⁴, Jean-Yves Gauvrit⁵, Nicolas Grenier⁶, Genevive Reinhardt⁷, Maurice Laville⁸, Nicolas Janus¹, Laurence Rouillon¹, Gabriel Choukroun⁹, Olivier Clment¹⁰

¹Service ICAR, Nephrology department, Pitie-Salpetriere Hospital, Paris, France; ²Nephrology, Pitie-Salpetriere Hospital, Paris, France; ³Pharmacovigilance, ANSM, Saint-Denis Cedex, France; ⁴Dermatology, Tenon Hospital, Paris cedex 20, France; ⁵Radiology, Pontchaillou Hospital, Rennes cedex 09, France; ⁶Radiology, Pellegrin Hospital, Bordeaux, France; ⁷Radiology, Haguenau Hospital, Haguenau, France; ⁸Nephrology, Edouard Herriot Hospital, Lyon, France; ⁹Nephrology, South Hospital, Amiens, France; ¹⁰Radiology, European G. Pompidou Hospital, Paris cedex 15, France

Nephrogenic Systemic Fibrosis (NSF) is a cutaneous disorder characterized by widespread tissue fibrosis. Although the exact physiopathology is still unknown, emergence of NSF has been linked with gadolinium based contrast media (GBCA). The Pro-FINEST study was supported by the French societies of dermatology, nephrology and radiology, and the university seminars of nephrology. The study was sponsored by the French drug agency (ANSM) and the French society of radiology. It aims at determining the prevalence of NSF after a Magnetic Resonance Imaging (MRI) examination, with or without GBCA, in chronic dialysis patients.